ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2463

Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis

Eric Toussirot1, Francois Aubin 1, maxime Desmarets 1, Daniel WENDLING 2, benoit Augé 3, jerome Gillard 4, olivier messica 4, Xavier Guillot 1, caroline Laheurte 5, elisabeth monnet 1 and gilles dumoulin 1, 1University Hospital, Besancon, France, 2Rheumatology, University Teaching Hospital (CHRU), Besançon, France, 3private office, besancon, France, 4Centre Hospitalier, Lons le Saunier, France, 5EFS, besancon, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: body composition, DEXA and adipose tissue, psoriasis, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Obesity is a leading comorbidity in both psoriasis (Pso) and psoriatic arthritis (PsA) and is associated with common metabolic complications and increased cardiovascular (CV) risk. Obesity is also a risk factor for the onset of these diseases. Body composition and fat distribution have been rarely evaluated in Pso and PsA. In this study, we aimed to characterize the fat mass distribution in patients with Pso or PsA compared to a control group, with a special emphasis on the android/visceral region.

Methods: case-control study (NCT02849795). Patients with Pso (plaque psoriasis) or PsA (CASPAR criteria) were evaluated. Each patient was paired to a control subject, recruited in the same outpatient population, and matched for sex, age and body mass index (BMI) category. Clinical assessment included BMI, anthropometric measurements (waist circumference, waist /hip ratio), disease activity (PASI for Pso, CPDAI for PsA) and the SCORE CV risk score. Laboratory parameters of inflammation (ESR, CRP, IL-6), lipid parameters (total cholesterol, LDL and HDL cholesterol, triglycerides), metabolic parameters (glycemia, insulin, HOMA), serum adipokines (total and high molecular weight [HMW] adiponectin, leptin, resistin and retinol binding protein 4 [RBP4]) were measured. Body composition (lean mass, fat mass) and fat distribution (android/gynoid regions and visceral fat) were evaluated (DEXA, Lunar GE, CoreScan). Our primary criteria was the fat mass in the android/visceral region. Comparisons between patients and controls were performed with paired t tests, between all groups with ANCOVA (adjusted for age, sex, and BMI category) and Tukey post-hoc tests. Pearson correlations between CV risk and fat mass were calculated within groups.

Results: 52 patients with Pso and 52 patients with PsA and their respective paired-control were evaluated (Table 1). Total fat mass was increased in Pso but not in PsA. Android fat and visceral fat were found higher in Pso (p< 0.05) while the fat mass measurements did not differ between the patients with PsA and their controls. Waist circumference was higher in patients with Pso compared to their controls. Leptin, leptin/fat mass ratio, and total adiponectin were elevated in PsA while only the HMW/total adiponectin ratio was decreased in Pso. Insulin levels and HOMA were increased in both Pso and PsA groups. Finally, RBP4 was higher in both Pso and PsA patients compared to their respective controls. In patients with Pso, android and visceral fat were correlated with SCORE (r=0.3, p=0.02 and r= 0.6, p < 0.0001 respectively). In ANCOVA analysis, visceral fat was higher in Pso patients (p=0.0029), with a trend toward higher android fat (p=0.055), compared to PsA patients.

Conclusion: visceral fat is increased in patients with Pso but not in PsA. In parallel, both groups showed an elevation of circulating RBP4. Patients with Pso and PsA were also characterized by metabolic disturbances as showed by the increase in HOMA, and specific adipokine changes. In the Pso group, visceral fat is associated with CV risk evaluated by SCORE. Weight control and reduction of fat mass, especially visceral fat mass, may thus be an important concern in patients with Pso and appears less relevant in PsA.


Table 1 ADIPSO

Table 1: clinical characteristics, laboratory parameters, serum adipokines, metabolic parameters and body composition measurements of patients with Pso and PsA and their respective control subjects -Quantitative variables are presented as mean ± standard deviation; Pso: psoriasis; PsA: psoriatic arthritis; * p <0.05; **p <0.01; ***p<0.005-.


Disclosure: E. Toussirot, None; F. Aubin, None; m. Desmarets, None; D. WENDLING, None; b. Augé, None; j. Gillard, None; o. messica, None; X. Guillot, None; c. Laheurte, None; e. monnet, None; g. dumoulin, None.

To cite this abstract in AMA style:

Toussirot E, Aubin F, Desmarets m, WENDLING D, Augé b, Gillard j, messica o, Guillot X, Laheurte c, monnet e, dumoulin g. Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/body-composition-and-fat-distribution-in-patients-with-psoriasis-or-psoriatic-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/body-composition-and-fat-distribution-in-patients-with-psoriasis-or-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology